|
|
|
| Pharmacology of Aripiprazole Combined with Haloperidol in the Treatment of Tics-coprolalia Syndrome Children and Its Effect on ASO Levels |
| HUANG Ting, LIU Xiumei, WANG Jingrong, CHEN Rong, CHEN Xin |
| First-author's address: Fujian Children's Hospital, Fuzhou 350001, China |
|
|
|
|
Abstract Objective: To investigate the effect of Aripiprazole combined with Haloperidol in the treatment of tics-coprolalia syndrome children, explore the pharmacological mechanism and observe the effect of combined treatment on antistreptolysin O (ASO) levels. Method: A total of 122 children with tics-coprolalia syndrome admitted to Fujian Children's Hospital from May 2021 to May 2022 were randomly divided into the control group and the observation group, with 61 cases each group. The control group was treated with Haloperidol, and the observation group was treated with Aripiprazole combined with Haloperidol. After 12 weeks of follow-up, clinical efficacy, neurological function indexes, ASO levels and adverse drug reactions were compared between the two groups. Result: After treatment, the Yale global tic severity scale (YGTSS) scores of motor tic and vocal tic in the observation group were lower than those in the control group, the differences were statistically significant (P<0.05); the total effective rate of the observation group was higher than that of the control group, the difference was statistically significant (P<0.05), the levels of dopamine (DA), 5-hydroxytryptamine (5-HT) and ASO in the observation group were lower than those in the control group, the level of γ-aminobutyric acid (GABA) was higher than that in the control group, the differences were statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Aripiprazole combined with Haloperidol can effectively improve motor tic and vocal tic symptoms in children with tics-coprolalia syndrome, and reduce the level of ASO, it is safety.
|
|
Received: 09 January 2023
|
|
|
|
|
|
|
